James Patterson, MD
Internal Medicine · Memphis, TNNPI 1457352106
Payments from drug & device makers
Across 397 payments — averaging $20.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$2K
- Gilead$879
- Novo Nordisk$862
- Theratechnologies Inc.$775
- Merck$750
- AstraZeneca$669
- plus $3K from 23 others
What the payments were for
- Consulting fees$1,00012%
- Travel & lodging$501%
- Food & beverage$7,08986%
- Education$641%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 48 | $1,661 |
| Gilead | 46 | $879 |
| Novo Nordisk | 51 | $862 |
| Theratechnologies Inc. | 35 | $775 |
| Merck | 39 | $750 |
| AstraZeneca | 40 | $669 |
| GSK | 22 | $411 |
| Viiv Healthcare Company | 19 | $365 |
| Bayer | 15 | $304 |
| AbbVie | 15 | $266 |
| Abbott | 10 | $203 |
| Astellas Pharma US Inc | 5 | $151 |
| Johnson & Johnson(2 entities) | 8 | $134 |
| Sanofi-aventis U.S. LLC | 8 | $120 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $98 |
| Boehringer Ingelheim | 5 | $95 |
| Pfizer | 4 | $74 |
| Exact Sciences | 4 | $63 |
| Kowa Pharmaceuticals America, Inc. | 4 | $59 |
| Hikma Pharmaceuticals USA | 3 | $52 |
| Amarin Pharma, Inc. | 2 | $48 |
| Edwards Lifesciences | 1 | $31 |
| Myriad Genetic Laboratories, Inc. | 1 | $25 |
| Amgen | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
How this compares
$8,202 in reported general payments places this provider in the 90th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 112 | $125,593 |
| JardianceEmpagliflozin | 121 | $123,055 |
| OzempicSemaglutide | 113 | $110,339 |
| FarxigaDapagliflozin Propanediol | 106 | $93,914 |
| EliquisApixaban | 73 | $79,173 |
| JanuviaSitagliptin Phosphate | 62 | $75,705 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $54,683 |
| TrulicityDulaglutide | 40 | $44,642 |
| XareltoRivaroxaban | 37 | $32,891 |
| RybelsusSemaglutide | 14 | $32,548 |
| LinzessLinaclotide | 20 | $24,471 |
| Tresiba Flextouch U-100Insulin Degludec | 31 | $19,432 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 17 | $17,033 |
| EntrestoSacubitril/Valsartan | 12 | $15,191 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $10,319 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,661 | $170,235152 claims |
| Novo NordiskOzempic, Rybelsus | $862 | $142,887127 claims |
| Boehringer IngelheimJardiance | $95 | $123,055121 claims |
| AstraZenecaFarxiga, Symbicort | $669 | $102,820121 claims |
| PfizerEliquis | $74 | $79,17373 claims |
| MerckJanuvia | $750 | $75,70562 claims |
| GSKTrelegy Ellipta | $411 | $54,68353 claims |
| Johnson & JohnsonXarelto | $134 | $32,89137 claims |
| AbbVieLinzess | $266 | $24,47120 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $120 | $17,03317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Memphis
- Phillip NorthcrossMemphis$39K
- Lawrence WhitlockMemphis$36K
- Angela WatsonMemphis$32K
- William CushmanMemphis$24K
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
- Amanda Moore MillerKnoxville$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.